Cargando…

Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer

Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical management. The approach uses cytoreductive surgery which combines peritonectomy and visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the peritoneal cavity is...

Descripción completa

Detalles Bibliográficos
Autores principales: Harmon, Rhonda L, Sugarbaker, Paul H
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549516/
https://www.ncbi.nlm.nih.gov/pubmed/15701175
http://dx.doi.org/10.1186/1477-7800-2-3
_version_ 1782122422025060352
author Harmon, Rhonda L
Sugarbaker, Paul H
author_facet Harmon, Rhonda L
Sugarbaker, Paul H
author_sort Harmon, Rhonda L
collection PubMed
description Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical management. The approach uses cytoreductive surgery which combines peritonectomy and visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the peritoneal cavity is flooded with chemotherapy solution in an attempt to eradicate residual disease. In order to select patients for this approach the quantitative prognostic indicators for carcinomatosis were reviewed, compared and contrasted. Prognostic indicators to be used to select patients for this aggressive approach at the initiation of surgery and after completion of cytoreduction were studied. Four quantitative assessments to be used at the time of abdominal exploration were the Gilly staging, Japanese gastric cancer P score, peritoneal cancer index (PCI), and the simplified peritoneal cancer index (SPCI). All have value with the PCI being the most validated and most precise. Preoperative assessments include the tumor histopathology and the prior surgical score. The completeness of cytoreduction score is an assessment of residual disease after a maximal surgical effort. An opportunity for long-term survival following treatment for carcinomatosis requires a complete cytoreduction in all reports for gastrointestinal cancer. Quantitative prognostic indicators need to be knowledgeably employed when patients with carcinomatosis are being treated. Improved patient selection with greater benefit and reduced morbidity and mortality should result.
format Text
id pubmed-549516
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-5495162005-02-25 Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer Harmon, Rhonda L Sugarbaker, Paul H Int Semin Surg Oncol Review Peritoneal carcinomatosis from gastrointestinal cancer has new treatment options for surgical management. The approach uses cytoreductive surgery which combines peritonectomy and visceral resection in an effort to remove all visible cancer within the abdomen and pelvis. Then the peritoneal cavity is flooded with chemotherapy solution in an attempt to eradicate residual disease. In order to select patients for this approach the quantitative prognostic indicators for carcinomatosis were reviewed, compared and contrasted. Prognostic indicators to be used to select patients for this aggressive approach at the initiation of surgery and after completion of cytoreduction were studied. Four quantitative assessments to be used at the time of abdominal exploration were the Gilly staging, Japanese gastric cancer P score, peritoneal cancer index (PCI), and the simplified peritoneal cancer index (SPCI). All have value with the PCI being the most validated and most precise. Preoperative assessments include the tumor histopathology and the prior surgical score. The completeness of cytoreduction score is an assessment of residual disease after a maximal surgical effort. An opportunity for long-term survival following treatment for carcinomatosis requires a complete cytoreduction in all reports for gastrointestinal cancer. Quantitative prognostic indicators need to be knowledgeably employed when patients with carcinomatosis are being treated. Improved patient selection with greater benefit and reduced morbidity and mortality should result. BioMed Central 2005-02-08 /pmc/articles/PMC549516/ /pubmed/15701175 http://dx.doi.org/10.1186/1477-7800-2-3 Text en Copyright © 2005 Harmon and Sugarbaker; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Harmon, Rhonda L
Sugarbaker, Paul H
Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title_full Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title_fullStr Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title_full_unstemmed Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title_short Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
title_sort prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549516/
https://www.ncbi.nlm.nih.gov/pubmed/15701175
http://dx.doi.org/10.1186/1477-7800-2-3
work_keys_str_mv AT harmonrhondal prognosticindicatorsinperitonealcarcinomatosisfromgastrointestinalcancer
AT sugarbakerpaulh prognosticindicatorsinperitonealcarcinomatosisfromgastrointestinalcancer